Paradigm Biopharmaceuticals makes key acquisition moving into FY26
Paradigm Biopharmaceutical (ASX: PAR) has opened the purse strings to pick up Proteobioactives Pty Ltd, which has been working on Pentacoxib, an early-stage oral candidate for minor to mild osteoarthritis.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest hea...
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online